The upper and lover
respiratory tract infections are usually mild and self-limited. Owing to their frequency recurrent upper and lower
respiratory tract infection in children and adults constitute a major global health problem. The goal of our study was to observe 30 children with recurrent
respiratory tract infection, 17 boy and 13 girl, they were treated with
Ribomunyl. The control group consisted of 15 children who received only basic
therapy (10 boys and 5 girls). The age of the children ranged between 8 months and 6 years. The study was conducted by the simply randomization method. Clinical and laboratory examinations were evaluated before and
after treatment. The concentration of INF-gamma was rather low in study group in comparison with control group before the beginning of the treatment, that indicates insufficient stimulation of T-lymphocytes in children with
recurrent infection. INF-gamma lever significantly increased
after treatment (Statistically significantly P<0.05) in study group in comparison with control group.
Neopterin level unlike INF-gamma in study group was higher than in the control group, before and
after treatment. This fact can be explained that
neopterin as a slowly acting biologically active substance remains high during the presence of
recurrent infections.
Ribomunyl treatment significantly increased the level of
neopterin. The efficacy of the product is primarily confirmed by significant reductions in the number of
recurrent infections episodes and the use of antibacterials. Combined immunostimulating effect of
Ribomunyl makes it possible to use
Ribomunyl to create a longterm postvaccinal protection of the child.